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Summary
Background.— Transcarotid access is an alternative route for transcutaneous aortic valve
implantation (TAVI) in patients with impossible transfemoral access.
Aims.— We evaluated the safety, effectiveness and early and late clinical outcomes of
CoreValve
®
implantation via the common carotid artery.
Methods.— Eighteen patients (10 men, 8 women; mean age 84± 5 years) at high surgical
risk (mean EuroSCORE II 16± 13%) with signiﬁcant peripheral artery disease underwent TAVI
via common carotid artery access under general anaesthesia. Mean aortic valve area was
0.64± 0.13 cm2 (0.36± 0.07 cm2/m2).
Results.— At a mean follow-up of 605± 352 days, two patients (11%) had died in hospital,
on days 6 and 20, as a result of sepsis with multiorgan failure (n = 1) or pneumonia (n = 1).
There were no perioperative deaths, myocardial infarctions or strokes. Perioperative prosthesis
Abbreviations: CCA, common carotid artery; CT, computed tomography; TAVI, transcatheter aortic valve implantation.
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embolization occurred in one patient (6%), requiring implantation of a second valve. In-hospital
complications occurred in four patients (23%): blood transfusion for transient signiﬁcant bleed-
ing at the access site in one patient (6%); permanent pacemaker implantation in two patients
(11%); and pericardial drainage in one patient (6%). The rate of event-free in-hospital stay was
66%. Post-procedural echocardiography showed very good haemodynamic performance, with
a mean gradient of 8± 3mmHg. Moderate paravalvular leak was present in one patient (6%).
Mean intensive care unit stay was 48± 31 h; mean in-hospital stay was 7± 3 days.
Conclusion.— TAVI performed by transcarotid access in this small series of severely ill patients
was associated with a low incidence of complications, which were associated with the procedure
itself rather than the access route.
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Résumé
Justiﬁcation.— l’abord transcarotidien est une alternative à la voie transfémorale pour la mise
en place d’une prothèse valvulaire aortique par voie transcutanée (TAVI).
Objectif.— nous avons évalué la sécurité, l’efﬁcacité ainsi que les évènements à court et moyen
termes après implantation d’une valve CoreValve, en utilisant la voie de l’artère carotide
commune.
Méthode.— 18 patients, 10 hommes, 8 femmes, d’âge moyen 84± 5 ans, à haut risque chirur-
gical (EuroScore II moyen 16± 13) porteurs d’une artériopathie périphérique signiﬁcative ont
bénéﬁcié d’un TAVI en utilisant la voie de l’artère carotide commune, sous anesthésie générale.
La surface valvulaire aortique moyenne était de 0,64± 0,13 mc2 (soit une surface aortique
indexée à 0,36± 0,07 cm2/m2).
Résultats.— lors d’un suivi moyen de 605± 352 jours, deux patients (11%) sont décédés pendant
la phase hospitalière à J6 et J20 du fait d’un sepsis lié à une défaillance multiviscérale (1
patient) et du fait d’une pneumonie (1 patient). Il n’y a pas eu de décès péri-opératoire,
d’infarctus du myocarde ou d’accident ischémique cérébral. L’embolisation péri-opératoire
de la prothèse a été observée chez un patient soit 6% nécessitant l’implantation d’une sec-
onde valve. Les complications en phase hospitalière sont survenues chez 4 patients soit 23%.:
transfusion globulaire pour un saignement transitoire au site d’accès chez un patient (6%),
implantation permanente d’un pacemaker chez 2 patients (11%), et drainage péricardique chez
un patient (6%). Le taux actuariel de survie sans évènement est de 66% lors de ce suivi évolutif
de près de deux ans. L’échographie post-procédurale a montré la performance hémodynamique
satisfaisante avec un gradient moyen post-procédural de 8± 3mmHg. Une régurgitation par-
avalvulaire modérée a été décrite chez un seul patient (6%), le séjour moyen en soins intensifs au
décours de l’intervention était de 48± 31 heures, et la durée de séjour hospitalier de 7± 3 jours.
Conclusion.— le TAVI par voie carotide commune dans cette série préliminaire de patients
porteurs de sténose aortique sévère avec des comorbidités majeures semble sûr avec une inci-
dence faible de complications. Les complications sont dominées par celles liées à la procédure
elle-même et ne sont pas liées à la voie carotidienne.
Background
TAVI has emerged as a current routine alternative procedure
for treating severe aortic valve stenosis in patients who are
inoperable and at high surgical risk [1]. Transfemoral access
is the most commonly used route [2—6]. However, patients
with limited vascular access caused by severe calciﬁcation
or tortuosity, previous iliofemoral surgery, type B aortic
dissection or surgically treated type A aortic dissections
may not be candidates for transfemoral access. For these
patients, the need for TAVI has led to the development of
transapical, transaortic and transaxillary/transsubclavian
alternatives. Generally, a patent left internal thoracic
artery coronary bypass graft precludes left transsubclavian
access because of the risk of coronary hypoperfusion by
the 18 F delivery sheath positioned in the left subclavian
artery. An implantable pacemaker/deﬁbrillator in the
subclavian region may also restrict transsubclavian access.
Transapical or transaortic accesses both require thoraco-
tomy or mini-sternotomy. Transcarotid access has been
slowly gaining popularity as an alternative in the growing
TAVI arena when other routes are not feasible. The purpose
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of  our  prospective  study  was  to  assess  the  feasibility
and safety  of  transcarotid  access  for  a speciﬁc  group  of
patients.
Methods
Patient selection
Since  November  2012,  18  consecutive  patients  (10  men
and 8  women)  with  peripheral  artery  disease  and  severe
symptomatic aortic  stenosis  underwent  the TAVI  procedure
via transcarotid  access.  These  patients  were  not eligi-
ble for  cardiac  surgery  because  of multiple  co-morbidities
and a  high  perioperative  risk.  Each  patient  was  selected
for TAVI  after  multidisciplinary  heart  team  evaluation.  All
patients  underwent  routine  preoperative  coronary  angiogra-
phy, transthoracic  echocardiography  and contrast-enhanced
cardiac computed  tomography  (CT).  Transcarotid  artery
access was  chosen  when  transfemoral  access  was  not
suitable because  of severe  peripheral  arteriopathy,  major
tortuosity or previous  iliofemoral  surgery.  The  patency
and anatomy  of  the  carotid  artery  were  evaluated  pre-
operatively with  contrast-enhanced  CT.  All  patients  had
preoperative functional  assessment  of the  carotid  artery  by
transcranial Doppler  examination.
Procedure
Procedures  were  performed  by  a multidisciplinary  team  that
included anaesthesiologists,  interventional  cardiologists  and
cardiac surgeons,  with  patients  under  general  anaesthesia
and transoesophageal  echocardiographic  monitoring.  Aspirin
100 mg/day  was  started  the day  before the  procedure,  with-
out additional  antiplatelet  agents.  Patients  received  1.5  g
of  cefuroxime  by  intravenous  injection  immediately  before
the incision.  All  procedures  except  one were  performed  via
the right  common  carotid  artery  (CCA).  After intravenous
injection of  5000  U  of  unfractionated  heparin,  a  surgical
cut-down of the right  CCA  was  performed,  and  an  18  F
sheath was  inserted  directly  into  the right  CCA for  intro-
duction of  the valve delivery  system  (CoreValve
®
ReValving
System; Medtronic,  MN,  USA).  Cerebral  oximetry  monitoring
was performed  during  the  procedure,  based  on  near  infrared
spectroscopy during the  procedure  to  detect  ischaemic
cerebral complications.  An  aortic  root  pigtail  catheter  was
advanced through  a  5 F arterial  sheath  in  the femoral  artery
for angiographic  visualization.  A temporary  pacemaker  lead
was inserted  via the  femoral  vein through  a  6  F  sheath.  A
stiff wire  (SafariTM pre-shaped  TAVI  guidewire;  Boston  Scien-
tiﬁc, Marlborough,  MA,  USA)  was  used  for  guiding  the valve.
No balloon  aortic  valvuloplasty  was  performed  before  TAVI
implantation. After the  valve  was  delivered,  the  sheath  was
retrieved, and the CCA  was  surgically  purged  and  repaired
with the  aid  of  a 6-0 polypropylene  suture.  A drain  was
inserted, and  the incision  was  closed  (Figs.  1  and  2).  Patients
were then  transferred  to  the intensive  care  unit.  Transtho-
racic echocardiography  was  used  to  assess  the  prosthetic
valve function  on  day  1 and  during  follow-up  at  1 and  6
months.
Figure 1. a: positions of  the operators, with the ﬁrst operator
on  the left and the second operator on the right: it is evident that
only  the ﬁrst operator sees the ﬂuoroscopy; the material has to be
improved  for this access; b: picture of  the access site after valve
implantation, just before sheath removal by the surgeon.
Results
Overall,  18  consecutive  patients  ineligible  for  transfemoral
access (10  men, 55%; eight  women,  45%), with  a mean
EuroSCORE II of  16  ±  13%  and  signiﬁcant  peripheral  artery
disease, underwent  TAVI  for  severe  symptomatic  aortic
stenosis via right  CCA access  under  general  anaesthesia.  The
mean age  was  84  ±  5 years  and the mean  aortic  valve  area
was 0.64  ±  0.13  cm2 (0.36  ±  0.07  cm2/m2). Baseline  patient
characteristics  and  preoperative  demographic  data  are  sum-
marized in Table  1.  As  shown  in Table  2,  seven  patients  with  a
mean EuroSCORE  II  <  10%  were  considered  for  TAVI,  although
Table  1  Preoperative  demographic  data  and  baseline
patient  characteristics  (n = 18).
Age  (years) 84  ±  5
Men 10  (55)
Body  mass  index  (kg/m2)  26  ±  4
New York  Heart  Association  class  III/IV  10  (55)
Pacemaker  carrier  3  (17)
Peripheral  vascular  disease  18  (100)
Renal  failure  11  (61)
History  of  coronary  artery  bypass  graft  2  (11)
Left  ventricular  ejection  fraction  (%) 56  ±  16
Aortic annular  surface  (cm2) 0.65  ±  0.12
EuroSCORE II (%) 16  ±  13
Data are expressed as mean ±  standard deviation or number
(%).
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Figure 2. a: position of the sheath immediately before deployment of the valve; the vertical position of the catheter facilitates the
delivery of the prosthesis; b: prosthesis after deployment.
Table 2 EuroSCORE II individual data (n = 18).
Patient EuroSCORE II (%)
1 22
2 15
3 8
5 5
5 16
6 16
7 15
8 5
9 5
10 31
11 27
12 51
13 6
14 12
15 6
16 7
17 17
18 28
Overall mean± standard deviation 16± 13
they were below the threshold. Four patients among them
categorically refused an open heart operation, two patients
had a porcelain aorta, and one patient had history of radia-
tion for lymphoma. Data, complications and safety outcomes
were collected in hospital at 30 days, 6 months and 1, 2 and 3
years (Tables 3 and 4). Prosthesis implantation was unevent-
ful in this series of patients. Transcarotid introduction of the
delivery sheath was successful, and accurate deployment of
the device was achieved in all cases. No carotid dissections
occurred during the procedures.
At a mean follow-up of 605± 352 days, two patients
(11%) had died, as shown in Table 3. There were no intra-
operative deaths. There was one in-hospital death on day
6 of an 85-year-old patient with very poor preoperative
condition (EuroSCORE II 51, left ventricular ejection frac-
tion 25%), caused by sepsis and low cardiac output syndrome
with multisystem organ failure. The second death occurred
in an 83-year-old patient known to have monoclonal
Table 3 Procedural data and in-hospital data and
complications (n = 18).
Variable N (%)
Procedural data
Procedural success 18 (100)
Valve malpositioning 1 (6)
Carotid dissection 0 (0)
Conversion to open surgery 0 (0)
Acute renal failure 0 (0)
Major access site bleeding 1 (6)
Procedural mortality 0 (0)
Permanent pacemaker for complete
AV block
2 (11)
Postimplantation mean gradient
(mmHg)
8± 3
Aortic regurgitation grade III/IV 0 (0)
Intensive care unit stay (h) 48± 31
In-hospital stay (days) 7± 3
In-hospital events
Death 2 (11)
Myocardial infarction 0 (0)
Stroke 0 (0)
MACCE 2 (11)
Data are expressed as number (%) or mean± standard deviation.
AV: atrioventricular; MACCE: major adverse cerebrovascular or
cardiovascular events.
Table 4 Late safety endpoints in mean follow-up
(605± 303 days; n = 18).
Variable n (%)
All-cause mortality 2(11)
New York Heart Association class III/IV 0(0)
Myocardial infarction 0(0)
Stroke and TIA 0(0)
MACCE 2(11)
MACCE: major adverse cerebrovascular or cardiovascular events;
TIA: transient ischaemic attack.
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gammopathy of undetermined signiﬁcance, who died on
day 20 because of pneumonia and sepsis. There was no
myocardial infarction as assessed by clinical symptoms,
periprocedural cardiac biomarker measurements, electro-
cardiograms and ventricular wall motion echocardiography
analysis. There was no stroke or transient ischaemic attack
as assessed by clinical criteria. Prosthesis embolization in
the ascending aorta occurred in one patient (6%) periop-
eratively, and required implantation of a second valve.
No prosthesis thrombosis, endocarditis or other compli-
cation associated with prosthetic valve implantation was
observed. Additional in-hospital complications occurred in
four patients (23%). One patient (6%) with active cirrhosis
required a blood cell transfusion for transient severe bleed-
ing at the vascular access site. One patient (6%) required
pericardial drainage because of tamponade at the time
of temporary pacemaker removal. Third-degree atrioven-
tricular block requiring permanent pacemaker implantation
occurred in two patients (11%). Event-free in-hospital stay
was 66%. Postprocedural echocardiography showed very
good haemodynamic performance of the CoreValve
®
, with
a mean gradient of 8± 3mmHg. There was no prosthetic
valve stenosis or prosthesis-patient mismatch at the 1-
and 6-month echocardiography assessments. Moderate par-
avalvular leak was present in one patient (6%). The mean
intensive care unit stay was 48± 31 h and the mean in-
hospital stay was 7± 3 days (Table 3).
Discussion
TAVI is widely accepted as a therapeutic option for patients
with symptomatic severe aortic valve stenosis at high sur-
gical risk because of multiple co-morbidities. TAVI, using
the Medtronic CoreValve
®
, was associated with signiﬁcantly
lower mortality at 1 year when compared with conven-
tional aortic valve replacement in patients at high surgical
risk [7]. Transfemoral access is generally considered to be
less invasive, and is thus the most widely used access for
TAVI, with ongoing improvements in technical feasibility,
including reduced sheath proﬁles and automated closure
percutaneous devices. However, given the high incidence
of vascular disease in TAVI candidates, an alternate access
route is required when iliofemoral artery access is problem-
atic, because of severe arteriopathy, tortuosity or previous
surgery.
In many centres, the transapical route is well established
as a second option, as its use is supported by feasibility data
with favourable clinical outcomes [8—10]. The short dis-
tance between access and deployment sites facilitates valve
insertion and placement. However, the need for thoraco-
tomy and left ventricular cannulation may not be suitable for
certain patients with severe left ventricular dysfunction or
lung disease. Moreover, bleeding complications, lateroapical
hypokinesia and ventricular aneurysm formation have been
reported [6,11,12].
In 2010, Modine et al. reported the ﬁrst experience
of a successfully performed TAVI through the left CCA,
complicated by retrograde dissection of the latter and
the ascending aorta, leading to transient hemiparesis [13].
Later, Modine et al. further reported successful implan-
tation of a self-expanding valve via transcarotid access,
with one transient ischaemic attack (7%) and no vascular
access site complications as early outcomes in a series of
12 patients [14]. More recently, Azmoun et al. reported
no cerebrovascular events or access site complications in a
series of 19 patients undergoing TAVI of both self-expanding
and balloon-expandable valves via transcarotid access under
local anaesthesia [15]. To date, further available data seem
to conﬁrm the safety and feasibility of this access site
[16,17]. Furthermore, a ﬁrst report of valve-in-valve implan-
tation for degenerated stentless aortic root conduits with
severe regurgitation via transcarotid access has described
three uneventful cases [18].
In the present series of 18 consecutive patients, we
have shown that transcarotid access might be a suitable
alternative access for TAVI with excellent outcomes when
transfemoral or other access site routes are not feasible.
Prosthetic valve positioning and release control are eas-
ier and the transcarotid approach offers greater movement
precision compared with the transsubclavian or transaortic
routes as a result of the shorter distance and the direct tra-
jectory between the carotid artery and the aortic annulus.
Furthermore, transcarotid access is feasible in patients with
a previous coronary artery bypass graft, who are at risk of
myocardial hypoperfusion when a transaxillary approach is
employed.
In our prospective study of this small series of patients
there were no cerebrovascular ischaemic events. Stroke is
a main concern in TAVI procedures [19], and is caused by
cerebral embolic events from valvular calciﬁcations or aor-
tic atheroma. As the transcarotid access does not include
instrumentation of the aortic arch, and the carotid artery is
surgically purged after sheath retrieval, cerebral emboliza-
tion events can be reduced. In our study, access-site
complications occurred in one patient with active cirrhosis,
and involved major bleeding of the access site, requiring a
blood cell transfusion event. There were no intraoperative
deaths in our series. One in-hospital death occurred on day
6 in an 85-year-old patient in poor preoperative condition,
with a EuroSCORE II of 51 and a left ventricular ejection
fraction 25%, and was the result of sepsis and multisystem
organ failure. The second death, on day 20, was in an 83-
year-old patient known to have monoclonal gammopathy of
undetermined signiﬁcance, and was the result of pneumonia
and sepsis. Both deaths were unrelated to the transcarotid
access procedure itself.
Study limitations
An important limitation of the current prospective study
was the small size of the population, which undermined the
statistical power of the study. These preliminary data do
not allow us to draw any deﬁnite conclusions regarding the
safety of this access site route.
Conclusion
TAVI performed by transcarotid access in this small series
of aged and severely ill patients was feasible with a low
incidence of short- and long-term complications. These
complications were related to the procedure itself and not
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to the access route. Our results highlight growing interest in
a larger conﬁrmatory study.
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